The definition of long COVID used in interventional studies von Haslam, Alyson, Olivier, Timothée, Prasad, Vinay

Volltext

Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action von Olivier, Timothée, Haslam, Alyson, Prasad, Vinay

Volltext

Equal censoring but still informative: When the reasons for censoring differ between treatment arms von Olivier, Timothée, Prasad, Vinay

Volltext

The fate of sotorasib: a regulatory failure potentially harming patients von Ranganathan, Sruthi, Prasad, Vinay, Olivier, Timothée

Volltext

Tumor Treating Fields therapy in metastatic non-small-cell lung cancer von Olivier, Timothée, Addeo, Alfredo

Volltext

Sotorasib in KRASG12C mutated lung cancer von Olivier, Timothée, Prasad, Vinay

Volltext

Shrinking sample sizes in lung cancer trials: Various explanations, open questions von Olivier, Timothée, Addeo, Alfredo

Volltext

The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA von Olivier, Timothée, Prasad, Vinay

Volltext

Molecular testing to deliver personalized chemotherapy recommendations: risking over and undertreatment von Olivier, Timothée, Prasad, Vinay

Volltext

Frontline Dual Checkpoint Inhibition in Metastatic Melanoma Over Anti-PD-1 Monotherapy: The Case for a Comparative Randomized Controlled Trial von Olivier, Timothée, Prasad, Vinay

Volltext

PARP inhibitors and overall survival in ovarian cancer, reevaluation advised in all settings von Olivier, Timothée, Prasad, Vinay

Volltext

Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020 von Olivier, Timothée, Haslam, Alyson, Prasad, Vinay

Volltext

FDA precedents in drug approvals: Contradiction in promoting more treatment options von Olivier, Timothée, Prasad, Vinay

Volltext

CDK4/6 inhibitors as adjuvant therapy in early breast cancer? Uncertain benefits, guaranteed harms von Haslam, Alyson, Ranganathan, Sruthi, Prasad, Vinay, Olivier, Timothée

Volltext

Progression-free survival estimates are shaped by specific censoring rules: Implications for PFS as an endpoint in cancer randomized trials von Lesan, Vadim, Olivier, Timothée, Prasad, Vinay

Volltext

Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current Guidelines von Olivier, Timothée, Prasad, Vinay

Volltext

Tebentafusp in first-line melanoma trials: An outperforming outlier von Olivier, Timothée, Prasad, Vinay

Volltext

Health-related quality of life in trials with high rates of early censoring: Caution advised von Olivier, Timothée, Haslam, Alyson, Prasad, Vinay

Volltext

Prostate-specific Membrane Antigen Positron Emission Tomography in the Staging of Newly Diagnosed Prostate Cancer: Is More Sensitivity Always Better? von Varatharajan, Abirramy, Olivier, Timothée, Prasad, Vinay

Volltext

Informative censoring due to missing data in quality of life was inadequately assessed in most oncology randomized controlled trials von Olivier, Timothée, Haslam, Alyson, Prasad, Vinay

Volltext